48 active not recruiting, 13 completed, 5 recruiting, 2 terminated. 71 Phase 2, 17 Phase 1.
Follow Refractory Malignant Solid Neoplasm: new trials by email Literature Review of Refractory Malignant Solid Neoplasm trials Research Report on Refractory Malignant Solid Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma Bcl-XL Proteolysis Targeting Chimera DT2216, Biospecimen Collection, Irinotecan - Childhood Fibrolamellar Carcinoma, Recurrent Childhood Fibrolamellar Carcinoma | Phase 1 / Phase 2 | Suspended | Children's Oncology Group | 81 | 2025-06-12 | 2026-08-24 |
| Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors Axatilimab, Biopsy, Biospecimen Collection - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 / Phase 2 | Recruiting | OHSU Knight Cancer Institute | 38 | 2024-05-21 | 2026-07-08 |
| Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 40 | 2023-07-14 | 2026-08-04 |
| Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors Atezolizumab, Biospecimen Collection, Computed Tomography - Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 86 | 2022-11-17 | 2026-07-14 |
| Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors BET Bromodomain Inhibitor ZEN-3694, Computed Tomography, Core Biopsy - Advanced Malignant Solid Neoplasm, Locally Advanced Pancreatic Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 49 | 2022-11-16 | 2026-07-15 |
| Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) Biopsy, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2022-02-22 | 2024-05-06 | |
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy - Diffuse Midline Glioma, H3 K27-Altered, Metastatic Malignant Neoplasm in the Central Nervous System | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 63 | 2022-01-28 | 2026-09-11 |
| Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors Elimusertib - Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 31 | 2021-12-22 | 2026-01-23 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint - Colorectal Carcinoma, Endometrial Carcinoma | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 147 | 2021-11-08 | 2026-08-25 |
| Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma Onivyde, Talazoparib, Temozolomide - Recurrent Solid Tumor, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 90 | 2021-06-09 | 2026-05-19 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Etoposide - Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 2 | Terminated | M.D. Anderson Cancer Center | 1 | 2020-08-19 | 2025-06-29 |
| Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Ivosidenib - Recurrent Ependymoma, Recurrent Ewing Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 3 | 2020-07-20 | 2026-07-01 |
| Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors Avelumab, Berzosertib - Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 23 | 2020-03-17 | 2026-06-11 |
| Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Malignant Solid Neoplasm, Refractory Cholangiocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2020-01-30 | 2026-08-03 |
| Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations Infigratinib - Advanced Malignant Solid Neoplasm, Cholangiocarcinoma | Phase 2 | Completed | Sameek Roychowdhury | 17 | 2020-01-16 | 2026-02-24 |
| Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2019-08-08 | 2026-06-01 |
| Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2019-07-24 | 2026-10-15 |
| AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification Adavosertib - Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 2 | Completed | National Cancer Institute (NCI) | 31 | 2019-01-16 | 2023-10-17 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-11-14 | 2026-09-21 |
Showing 20 of 71. Sign in to see all of them.
Lymphoma (39) · Multiple Myeloma (34) · Hematologic Neoplasms (21) · Neuroblastoma (18) · Osteosarcoma (15) · Rhabdomyosarcoma (15) · Hepatoblastoma (14) · Lymphoma, Non-Hodgkin (14) · Neuroectodermal Tumors, Primitive, Peripheral (14) · Wilms Tumor (14) · Rhabdoid Tumor (13) · Sarcoma (13) · Glioma (12) · Central Nervous System Neoplasms (11) · Ependymoma (11)
Neoplasms (68) · Neoplasms by Histologic Type (62) · Hemic and Lymphatic Diseases (53) · Immune System Diseases (53) · Immunoproliferative Disorders (53) · Lymphatic Diseases (53) · Lymphoproliferative Disorders (53) · Neoplasms by Site (43) · Hematologic Diseases (35) · Blood Protein Disorders (34) · Cardiovascular Diseases (34) · Hemorrhagic Disorders (34) · Hemostatic Disorders (34) · Neoplasms, Plasma Cell (34) · Paraproteinemias (34)
Specimen Handling (29) · Biopsy (26) · Magnetic Resonance Spectroscopy (24) · X-Rays (12) · Nuclear Medicine Department, Hospital (10) · Phantoms, Imaging (8) · Crizotinib (6) · trametinib (6) · Nivolumab (4) · adavosertib (4) · erdafitinib (4) · larotrectinib (4) · palbociclib (4) · ulixertinib (4) · Afatinib (3)
National Cancer Institute (NCI) (60) · Children's Oncology Group (5) · M.D. Anderson Cancer Center (3) · OHSU Knight Cancer Institute (1) · Sameek Roychowdhury (1) · St. Jude Children's Research Hospital (1)
United States (70) · Puerto Rico (13) · Canada (8) · Australia (6) · Guam (1)
David S Hong (3) · Filip Janku (3) · Jason J Luke (2) · John L Hays (2) · Kevin M Kalinsky (2) · Michael V Ortiz (2) · Nilofer S Azad (2) · Patricia M LoRusso (2) · Shivaani Kummar (2) · Aaron S Mansfield (1) · AeRang Kim (1) · Alain C Mita (1) · Alice Lee (1) · Alice T Shaw (1) · Amy S Clark (1)
PMID 31401903, PMID 32463741, PMID 23598171, PMID 26586415, PMID 28032129, PMID 31765263, PMID 32192573, PMID 33048619, PMID 33568345, PMID 33591402, PMID 34486544, PMID 35133871, PMID 35138919, PMID 35353553, PMID 35363510, PMID 36351402, PMID 36469840, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38520670, PMID 38591867, PMID 38815151, PMID 38873934, PMID 38935895, PMID 39666929, PMID 39693587, PMID 39863139, PMID 39913886, PMID 39998620, PMID 40139261, PMID 40153687, PMID 40865033, PMID 41066729, PMID 41166674, PMID 41533998, PMID 41556942, PMID 41646361, PMID 41920422, PMID 42686334, PMID 42867148
U10CA180820 (37), U24CA196172 (21), U10CA180886 (13), UM1CA228823 (5), UM1CA097452 (4), UM1CA186689 (3), P30CA006516 (1), P50CA127003 (1), U01CA062490 (1), UM1CA081457 (1), UM1CA186688 (1), UM1CA186691 (1), UM1CA186705 (1), UM1CA186709 (1), UM1CA186717 (1)